PharmAthene (PIP) Presents Data on Anthrax Vaccine rPA at HHS PHEMCE Workshop; Vaccine Stable at Various Temps
More News related to PIP
- PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
- PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
- PharmAthene (PIP) Announces Presentation of Anthrax Anti-Toxin Valortim Data
- Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria
- Unusual 11 Mid-Day Movers 2/23: CIMT, SSE, IFLG, ZLC, PIP Higher; LIVE, BRCD, OWW, GLDD Lower
More News related to Corporate News
- Apple (AAPL) Accepting iPad Applications for Review Today; Telling Developers to Submit App by March 27 for April 3 Launch
- Alanco Technologies (ALAN) Receives Non-Compliance Notification From NASDAQ
- Fed ends exemptions to banks aimed at adding mortgage liquidity
- Citi (C) Reverses Decision to Shrink Home-Lending Business; To Boost Purchases of Mortgages Sold by Other Banks -Bloomberg
- IBM Announces Addition of 200 Partners to LotusLive Cloud Services
PharmAthene, Inc. (AMEX: PIP) announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C. The data were presented by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene, during an oral session at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 / BARDA Industry Day.
David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "These new data are very encouraging as they demonstrate that PharmAthene's lyophilized rPA could be used to provide a stable cold-chain-free vaccine, enabling us to develop a formulation which could be stored and distributed at room temperature, an important attribute for deployment in the civilian Strategic National Stockpile."
In an oral presentation entitled, "Development of a Highly Stable Lyophilized rPA-Based Anthrax Vaccine," Dr. Duchars presented results from a series of studies evaluating different approaches to increase the stability of an rPA anthrax vaccine product candidate. Of the techniques evaluated, lyophilization showed exceptional stability. An optimized lyophilized formulation of rPA was subsequently tested in an accelerated stability study at 5 degrees C; 25 degrees C; 40 degrees C; and 55 degrees C.
At 3 months, little evidence of rPA degradation was detected in the samples at all temperatures up to and including 55 degrees C. Using the mouse challenge assay, the lyophilized rPA vaccine was shown to have retained potency. Subsequent analysis at 16 months demonstrated that the rPA had retained both structural integrity and vaccine potency.
These preliminary data suggest that an optimized rPA formulation could be used to provide a stable cold-chain-free vaccine. Scale-up of the lyophilization process is currently underway.
Related Categories
Corporate NewsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
